磁共振生物标志物可预测杜氏肌营养不良临床功能
结果显示,股外侧肌FF、股外侧肌MRI T2及股二头肌长头MRI T2随时间进展最快,且下肢MR生物标志物可预测12和24个月后的功能表现与步行能力丧失。
要点
- 股外侧肌FF与MRI T2是进展最快的下肢MR生物标志物
- MR生物标志物可预测12和24个月后的步行功能
- 近端肌肉MR指标对预测步行能力丧失最有价值
核心结论
- 下肢MR生物标志物与DMD临床功能指标密切相关,尤其近端肌肉指标可预测未来步行功能与重要临床里程碑。
研究设计与样本
- 受试者在12、24、36和48个月返回进行随访数据收集。
主要发现
- 股外侧肌FF、股外侧肌MRI T2和股二头肌长头MRI T2是本以可行走受试者为主的队列中随时间进展最快的生物标志物。
- 生物标志物数值随时间呈非线性S形轨迹变化。
- 下肢生物标志物可预测12和24个月后的功能表现,且MR生物标志物随时间的变化幅度与功能变化幅度相关。
- 股外侧肌FF、比目鱼肌FF、股外侧肌MRI T2和股二头肌长头MRI T2是未来功能丧失(包括步行能力丧失)的最强预测指标。
临床怎么用
- 可将下肢MR生物标志物用于DMD临床试验终点评估,并用于预测未来步行功能与步行能力丧失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the potential of lower extremity magnetic resonance (MR) biomarkers to serve as endpoints in clinical trials of therapeutics for Duchenne muscular dystrophy (DMD) by characterizing the longitudinal progression of MR biomarkers over 48 months and assessing their relationship to changes in ambulatory clinical function. METHODS: One hundred sixty participants with DMD were enrolled in this longitudinal, natural history study and underwent MR data acquisition of the lower extremity muscles to determine muscle fat fraction (FF) and MRI T2 biomarkers of disease progression. In addition, 4 tests of ambulatory function were performed. Participants returned for follow-up data collection at 12, 24, 36, and 48 months. RESULTS: Longitudinal analysis of the MR biomarkers revealed that vastus lateralis FF, vastus lateralis MRI T2, and biceps femoris long head MRI T2 biomarkers were the fastest progressing biomarkers over time in this primarily ambulatory cohort. Biomarker values tended to demonstrate a nonlinear, sigmoidal trajectory over time. The lower extremity biomarkers predicted functional performance 12 and 24 months later, and the magnitude of change in an MR biomarker over time was related to the magnitude of change in function. Vastus lateralis FF, soleus FF, vastus lateralis MRI T2, and biceps femoris long head MRI T2 were the strongest predictors of future loss of function, including loss of ambulation. CONCLUSIONS: This study supports the strong relationship between lower extremity MR biomarkers and measures of clinical function, as well as the ability of MR biomarkers, particularly those from proximal muscles, to predict future ambulatory function and important clinical milestones. CLINICALTRIALSGOV IDENTIFIER: NCT01484678.
引用
- Barnard AM, Willcocks RJ, Triplett WT, et al. MR biomarkers predict clinical function in Duchenne muscular dystrophy. Neurology. 2020. PMID: 32024675. doi:10.1212/WNL.0000000000009012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。